Which companies overlap with B. Braun Ltd. Centre of Excellence Infection Control's portfolio?

Top competitors by shared drug class: Baycrest.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/b-braun-ltd-centre-of-excellence-infection-control.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-18 · How we verify

B. Braun Ltd. Centre of Excellence Infection Control — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

B. Braun Ltd. Centre of Excellence Infection Control pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Lavasept 0.04%	Lavasept 0.04%	marketed	Antimicrobial antiseptic	Bacterial cell membrane and proteins	Infection Control / Dermatology

Therapeutic area mix

Infection Control / Dermatology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Baycrest · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for B. Braun Ltd. Centre of Excellence Infection Control:

Cite this brief

Drug Landscape (2026). B. Braun Ltd. Centre of Excellence Infection Control — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/b-braun-ltd-centre-of-excellence-infection-control. Accessed 2026-05-18.